Abstract 334: Serum MicroRNA-378 as a Novel Diagnostic Biomarker for Myocardial Infarction
Purpose: Chest pain represents one of the most common reasons for a visit to the emergency department accounting for ~10% of all visits. Of these only 45% represented true acute coronary syndromes (ACS) (stable angina, unstable angina or myocardial infarction (MI)). The current methods to detect a true ACS have a clinic delay of several hours and hence it is the focus of our experiments to explore a novel diagnostic biomarker that can detect myocardial infarction more rapidly and reliably.
Methods and Results:In order to establish a library of potential diagnostic biomarkers, we developed a novel non-thoracotomy model of MI in the Ovis aries to minimize potential confounders of serum microRNA changes due to unrelated thoracotomy induced injuries. We obtained serum samples from different time points following MI and level of circulating microRNAs were detected by a microRNA array and compared to the concentration of Troponin I from the same sample. Among more than 300 identified microRNA in the array, 12 microRNA were tested with the highest fold expression change, and a single microRNA, miR-378, identified as a promising biomarker of MI. We used a mouse model of left coronary artery ligation induced MI to quantify the dynamics of miR-378 levels in response to MI injury (Figure) , we found miR-378 was non-detectable before MI, reached peak at 4 hours post MI; whereas Troponin I reached peak at 6 hours.
Conclusion:In both a large and small animal models of MI, microRNA-378 showed a reproducible time frame of peak expression that may serve as a more efficient diagnostic biomarker for myocardial infarction.
Author Disclosures: H. Zhu: None. A. Lagana: None. D. Veneziano: None. T. Adesanya: None. P. Mohler: None. M. Nishi: None. H. Takeshima: None. A. Kilic: None.
This research has received full or partial funding support from the American Heart Association.
- © 2014 by American Heart Association, Inc.